CARTemis Therapeutics is a spin-off of the Max Delbrück Center in Berlin, developing novel CAR T cell therapies to market-ready products with regulatory approval. Its portfolio consists of highly developed and differentiated CAR T-cell products using unique modes of action to overcome obstacles limiting durable success of CAR T cells in life-threatening hematologic malignancies. The two lead products are currently evaluated in publicly funded phase 1/2 academic clinical trials in Germany.